title: Drug treatment for mood disorders in pregnancy.
abstract: OBJECTIVE
  During the last few years, several researches, often showing contradictory findings, have investigated the safety of psychotropic medications used for treating mood disorders in pregnancy. Hence, the necessity exists to update this information constantly in order to ensure the safest option for the mother-infant pair.
  
  
  RESULTS
  The risk of fetal anomalies associated with early in-utero exposure to antidepressants seems to be increased after paroxetine and clorimipramine exposure, whereas prenatal exposure to nearly all antidepressants is linked to the potential onset of the Prenatal Antidepressant Exposure Syndrome. As regards classic mood stabilizers, the teratogenic risk historically reported with lithium should probably be softened, whereas valproate is the medication which shows the strongest association with fetal anomalies. An increased risk of autism-spectrum disorders and infant neurodevelopmental delay is also associated with valproate exposure through the placenta. No significant reproductive safety data are available on atypical antipsychotics, although such medications may indirectly increase the rate of fetal malformation by inducing gestational diabetes.
  
  
  CONCLUSIONS
  Avoiding the use of clorimipramine, paroxetine, valproate, and atypical antipsychotics during pregnancy is advisable. However, when starting or continuing pharmacological treatment during pregnancy, clinicians should consider not only the intrinsic iatrogenic risk of birth defects or perinatal complications, but also the general safety profile for the expectant mother. Indeed, specific adverse reactions (such as nausea, vomiting, constipation, and excessive weight gain) may aggravate the classic clinical findings of pregnancy, thus indirectly facilitating the occurrence of pregnancy complications and fetal and neonatal problems.
authors.affiliation: Department of Mental Health, ASL Salerno, Italy. salvatore_gentile@alice.it
authors.forename: Salvatore
authors.initials: S
authors.lastname: Gentile
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D019964:Mood Disorders / Q000188:drug therapy*; D018743:Perinatal Care; D011247:Pregnancy / Q000523:psychology*; D011295:Prenatal Care; D011297:Prenatal Exposure Delayed Effects; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment
chemical_list: D011619:Psychotropic Drugs